Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.

– Two praliciguat Phase 2 studies for diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) on track for data readouts in Q4 2019 – – Phase 2 study.

New biopharma startup Cyclerion Therapeutics has stumbled out of the gate, disclosing Wednesday that one of its lead drug candidates failed in a mid-stage study.

Activity in the biotech space is likely to pick up this week. Events are likely to be headlined by the annual JPMorgan Healthcare Conference. Biotech stocks closed 2019 with gains, although they underperformed ...

Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced topline results from its Phase 2 proof-of-concept study of praliciguat, a once-daily, orally available systemic sGC stimulator, in diabetic nephropathy. The study did not meet statistical significance on its primary endpoint of reduction in albuminuria from baseline as compared to placebo, measured by urine albumin creatinine ratio (UACR), but there was a trend toward improvement across the total intention-to-treat (ITT) study population.

Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it will host a webcast investor event, to be held in New York City, on Tuesday, September 17, 2019 from 8:00 a.m. to 10:00 a.m. Eastern Time. This first Cyclerion live investor event will focus on praliciguat, the company’s investigational, orally administered, once-daily systemic sGC stimulator designed for the treatment of serious cardiometabolic diseases. External subject matter experts – Dr. James Udelson of Tufts Medical Center and Dr. Barbara Gillespie of the University of North Carolina and Covance – and members of Cyclerion’s leadership team will review the role of the nitric oxide/sGC system in cardiorenal physiology, the praliciguat development program, and the ongoing Phase 2 clinical studies investigating praliciguat as a potential treatment for diabetic nephropathy and for HFpEF.

– Management to review the Company's sGC clinical pipeline programs: praliciguat for diabetic nephropathy, olinciguat for sickle cell disease, and IW-6463 for neurodegenerative.

Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced upcoming medical meeting presentations highlighting its commitment to sickle cell disease patients and supporting its therapeutic approach to treating the disease through sGC stimulation. Cyclerion will present at the Annual National Convention of the Sickle Cell Disease Association of America (SCDAA), held October 9-12 in Baltimore, and at the Annual Sickle Cell Disease and Thalassaemia Conference (ASCAT), held October 21-23 in London. Cyclerion and its collaborators will present new research from a sickle cell disease patient journey project.

Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it recently closed enrollment for both of its ongoing clinical studies. The Company also provided additional corporate updates.

CAMBRIDGE, Mass., Nov. 27, 2019 -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate.

– Results in 110 subjects demonstrate favorable safety, CNS pharmacokinetics, and evidence of target engagement – – Study underway in elderly subjects to further assess.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

A look at the shareholders of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) can tell us which group is most powerful...

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) shareholders should be happy to see the share price up 28% in the last...

Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing […]

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

Cyclerion Therapeutics, Inc. (CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced topline results from its CAPACITY Phase 2 proof-of-concept study of praliciguat, a once-daily, orally available systemic sGC stimulator, in heart failure with preserved ejection fraction (HFpEF). The study did not meet statistical significance on its primary endpoint of improved exercise capacity from baseline as compared to placebo, measured by cardiopulmonary exercise testing (CPET).

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 30.) Allergan plc (NYSE: AGN ) Arrowhead Pharmaceuticals ...

Ironwood (IRWD) beats on earnings and sales in the second quarter. Demand for Linzess remains strong.

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...